CORTEXYME, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 29th, 2019 • Cortexyme, Inc. • Biological products, (no disgnostic substances) • New York
Cortexyme, Inc., a Delaware corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Credit Suisse Securities (USA) LLC (“Credit Suisse”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and Credit Suisse are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [•] additional shares of Common Stock. The afores
CORTEXYME, INC. AMENDED & RESTATED INDEMNIFICATION AGREEMENTIndemnification Agreement • April 29th, 2019 • Cortexyme, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended & Restated Indemnification Agreement (this “Agreement”) is made as of , 201 by and between Cortexyme, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
